News >

Nivolumab Improves Survival in Pretreated Chinese NSCLC Patients

Jason M. Broderick @jasoncology
Published: Friday, Dec 01, 2017

Yi Long Wu, MD

Yi Long Wu, MD
Nivolumab (Opdivo) improved survival versus docetaxel in a predominantly Chinese population of patients with pretreated advanced or metastatic non–small cell lung cancer (NSCLC), according to Bristol-Myers Squibb (BMS), the manufacturer of the PD-1 inhibitor.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication